Disitertide (TFA)

• Description :

  Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer[1][2][3][4][5].

• Product Name Alternative :

  P144 (TFA)

• UNSPSC :

  12352209

• Target :

  Apoptosis; PI3K; TGF-beta/Smad

• Type :

  Peptides

• Related Pathways :

  Apoptosis; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/disitertide-tfa.html

• Solubility :

  H2O : < 0.1 mg/mL

• Smiles :

  O=C(O)C(F)(F)F.C[C@@H](O)[C@H](N)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(N[C@@H](C)C(N[C@@H](CCSC)C(N[C@@H](CCSC)C(N[C@@H](CCC(N)=O)C(N[C@H](C(O)=O)CC(N)=O)=O)=O)=O)=O)=O)CC1=CNC2=CC=CC=C12)=O)=O)=O)=O)=O)=O)=O)=O

• Molecular Formula :

  C68H109N17O22S2.xC2HF3O2

• Molecular Weight :

  1580.82 (free acid)

• References & Citations :

  [1]Cindy Neuzillet, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.|[2]Jun Yang, et al. Upregulation of microRNA‑590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor‑β1/phosphoinositide 3‑kinase/Akt signaling. Int J Mol Med. 2019 May;43 (5) :2212-2220.|[3]Wanming He, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019 Jun;38 (23) :4637-4654.|[4]Shan Shan Qiu, et al. Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice. PLoS One. 2015 Dec 31;10 (12) :e0144489.|[5]Gabriel Gallo-Oller, et al. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Cancer Lett. 2016 Oct 10;381 (1) :67-75.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Peptides

• Clinical Information :

  Phase 2

• Citation 01 :

  Funct Integr Genomics. 2024 Jul 12;24 (4) :123.|Int Immunopharmacol. 2024 Aug 21:141:112778.|Int J Surg. 2025 Jul 9.|Acta Histochem. 2023 Feb;125 (2) :152010.|Cancer Manag Res. 2018 Oct 10:10:4459-4470.|Cell Death Differ. 2021 Jan;28 (1) :219-232.|Cells. 2019 Jun 25;8 (6) :635.|Dig Dis Sci. 2021 Jun;66 (6) :1916-1927.|Eur Rev Med Pharmacol Sci. 2019 Aug;23 (3 Suppl) :9-16. |Front Immunol. 2017 Feb 3:8:91.|Int J Mol Med. 2019 May;43 (5) :2212-2220. |J BUON. 2021; 26 (2) : 435-443.|J Exp Clin Cancer Res. 2021 Feb 9;40 (1) :62.|Oncogene. 2019 Jun;38 (23) :4637-4654.|Dig Dis Sci. 2025 May;70 (5) :1799-1812.